Alessio M G, Falanga A, Consonni R, Bassan R, Minetti B, Donati M B, Barbui T
Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy.
Eur J Haematol. 1990 Aug;45(2):78-81. doi: 10.1111/j.1600-0609.1990.tb00421.x.
In a previous study we characterized cancer procoagulant (CP), a 68 kd cysteine proteinase which directly activates coagulation factor X in various subtypes (from M1 to M5) of acute non-lymphoblastic leukemia (ANLL). The aim of this study was to determine whether CP is also expressed by acute lymphoblastic leukemia (ALL) cells. Blasts from 25 ALL patients were extracted and tested for their procoagulant properties. 16 samples (64%) shortened the recalcification time of normal human plasma, and 9 (36%) did not. 8 of the 16 active samples showed properties compatible with CP, i.e. independence from factor VII in triggering blood coagulation and sensitivity to cysteine proteinase inhibitors. Selected samples also cross-reacted with a polyclonal antibody raised against purified CP. The specific activity of CP in ALL extracts was significantly lower than in most ANLL types previously studied (all but M4). These finding indicate that CP can be a property of the lymphoid phenotype although its expression may be lower than in the myeloid phenotype.
在之前的一项研究中，我们对癌促凝素（CP）进行了特性描述，它是一种68kd的半胱氨酸蛋白酶，可在急性非淋巴细胞白血病（ANLL）的各种亚型（从M1到M5）中直接激活凝血因子X。本研究的目的是确定CP是否也由急性淋巴细胞白血病（ALL）细胞表达。提取了25例ALL患者的原始细胞，并检测其促凝特性。16个样本（64%）缩短了正常人血浆的再钙化时间，9个样本（36%）则没有。16个活性样本中的8个表现出与CP相符的特性，即在触发血液凝固时不依赖因子VII且对半胱氨酸蛋白酶抑制剂敏感。选定的样本还与针对纯化CP产生的多克隆抗体发生交叉反应。ALL提取物中CP的比活性明显低于之前研究的大多数ANLL类型（除M4外的所有类型）。这些发现表明，CP可能是淋巴细胞表型的一种特性，尽管其表达可能低于髓细胞表型。
